TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE

Loss of tolerance in systemic lupus erythematosus (SLE) leads to the generation of autoantibodies, which accumulate in end-organs where they induce disease. Here we show that immunoglobulin (Ig)G2a and 2b autoantibodies are the pathogenic isotypes by recruiting FcγRIV expressing macrophages. Class switching, but not development, of IgM anti-self B cells to these pathogenic subclasses requires the innate immune receptor Toll-like receptor (TLR)9 and MyD88 signaling. In their absence, switching of autoreactive B cells to the IgG2a and 2b subclasses is blocked, resulting in reduced pathology and mortality. In contrast, switching of anti-self B cells to IgG1 is not perturbed and generation of nonautoreactive IgG2a and 2b antibodies is not impaired in TLR9-deficient mice. Thus, the TLR9 pathway is a potential target for therapeutic intervention in SLE.

Genetic susceptibility and environmental factors are responsible for the development of systemic lupus erythematosus (SLE). Mouse models of SLE, in particular, have provided signifi cant insights into the identifi cation of critical checkpoints and the molecular pathways that mediate the generation of this autoimmune disease (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12). These models have demonstrated that the loss of tolerance that initiates SLE results from the accumulated eff ect of multiple genetic defects, which culminates in the deposition of pathogenic IgG autoantibodies in end-organs such as the kidney, where they induce infl ammation resulting in pathological events (6). IgG anti-DNA autoantibodies are a general feature of lupus and the molecular mechanisms that result in the selection and expansion of anti-DNA autoantibodies have been suggested to involve the Toll-like receptors (TLRs). In particular, TLR9 and its signaling molecule MyD88 can provide a costimulatory signal in vitro for B cell stimulation by DNA (13,14). The DNA ligand for TLR9 may be provided in vivo by apoptotic bodies that are incompletely cleared in lupus and could thus lead to uncontrolled activation of the TLR9-MyD88 pathway and promote anti-DNA autoantibody generation (13)(14)(15)).
It has recently been shown that pediatric SLE patients have a failure to establish B cell tolerance early during B cell development, leading to increased numbers of antinuclear, anticytoplasmic, and polyreactive cells in the naive peripheral B cell pool (16,17). The increased frequency of autoreactive, naive B cells is thus suggested to be a prerequisite for the generation of autoantibodies and the development of lupus (17). A similar situation has been discussed in murine models of SLE with polyreactive autoantibodies deposited in the kidneys of these mice (18,19). These polyreactive antibodies recognize DNA as well as glomerular antigens (18,19) and are believed to be responsible for inducing proteinurea and thereby contribute to the pathology of SLE (19).
We have recently described a strain-specifi c SLE model in which loss of the IgG inhibitory Fcγ receptor RIIB molecule on the C57BL/6 background resulted in the accumulation of pathogenic autoantibodies in the kidney with the development of glomerulonephritis and premature mortality (2). Through the use of a B cell-intrinsic, anti-DNA knockin model (the 56R VDJ4 heavy chain transgene on the C57BL/6 background), we have shown that the C57BL/6 strain provided a susceptible background by virtue of its inability to The online version of this article contains supplemental material. The online version of this article contains supplemental material.
Loss of tolerance in systemic lupus erythematosus (SLE) leads to the generation of autoantibodies, which accumulate in end-organs where they induce disease. Here we show that immunoglobulin (Ig)G2a and 2b autoantibodies are the pathogenic isotypes by recruiting Fc RIV expressing macrophages. Class switching, but not development, of IgM anti-self B cells to these pathogenic subclasses requires the innate immune receptor Toll-like receptor (TLR)9 and MyD88 signaling. In their absence, switching of autoreactive B cells to the IgG2a and 2b subclasses is blocked, resulting in reduced pathology and mortality. In contrast, switching of anti-self B cells to IgG1 is not perturbed and generation of nonautoreactive IgG2a and 2b antibodies is not impaired in TLR9-defi cient mice. Thus, the TLR9 pathway is a potential target for therapeutic intervention in SLE.
completely edit the light chain repertoire associating with the 56R heavy chain, thus allowing for the emergence of anti-DNA B cells into the periphery (6). Although these mice developed circulating anti-DNA antibodies of the IgM isotype, they did not develop disease, consistent with previous observations in which IgG autoantibodies were frequently associated with disease in SLE models (6). Combining the 56R + .B6 mice with the FcγRIIB defi ciency was suffi cient to result in the accumulation of pathogenic IgG antibodies by permitting the expansion of anti-DNA IgG plasma cells with subsequent tissue deposition of autoantibodies in the glomeruli and glomerulonephritis (6).
Using these lupus models, we have examined the contribution of the TLR9/MyD88 pathway to the generation of anti-DNA/polyreactive autoantibodies and have observed a crucial role for these pathways in the class switching of anti-DNA-expressing B cells to the pathogenic IgG2a and 2b subclasses. The loss of TLR9 protected lupus-susceptible mice from the spontaneous development of these pathogenic anti-DNA subclasses, while not aff ecting the ability to class switch to exogenous antigens. The specifi city of the TLR9-MyD88 pathway to regulating a B cell-intrinsic, anti-DNA class switch to IgG2a and 2b is likely the result of the ability of this pathway to induce the transcription factor T-bet in B cells.

Pathogenic IgG subclasses in SLE
To determine if specifi c IgG subclasses were responsible for the pathological manifestations of the autoimmune disease in FcγRIIB −/− .B6 mice, we analyzed the IgG subclasses of the autoantibodies in the serum and IgG subclasses deposited in the kidneys of these mice (Fig. 1, A and B). IgG autoantibodies in the serum as well as IgG depositions in the kidney of these mice were mainly of the IgG2a and IgG2b subclasses. IgG1 and IgG3 autoantibodies were underrepresented. IgG depositions were undetectable in wt.B6 mice (unpublished data). The observation that these subclasses dominated in this systemic autoimmune disease suggested a mechanism that could account for the severity of tissue

ARTICLE
destruction observed in this model. IgG2a and 2b are the most pathogenic subclasses in vivo by virtue of their unique ability to engage the recently described activation Fcγ receptor FcγIV (20). In contrast, IgG1 antibodies are signifi cantly less pathogenic, resulting from their preferential engagement of the inhibitory FcγRIIB molecule (20). FcγRIV-expressing macrophages accumulated in the kidneys of FcγRIIB −/− .B6 mice, but not in the kidneys of wt.B6 mice ( Fig. 1 C and not depicted) and are likely to have induced the kidney pathology in SLE.
In addition to the anti-DNA antibodies that accumulated in the FcγRIIB −/− .B6 background, we detected IgG2a and 2b subclass-restricted autoantibodies in the serum capable of recognizing both cardiolipin and glomerular basement membrane antigens (Fig. 2). Preabsorbing the serum with glomerular basement membrane (GBM) and cardiolipin antigens reduced the level of autoantibodies recognizing DNA, suggesting that at least a component of the subclass-restricted autoantibodies were polyreactive (Fig. 2).

MyD88 defi ciency protected against class switching to pathogenic IgG2a and 2b anti-DNA/polyreactive autoantibodies in SLE
We further investigated the molecular basis for the selective switching of autoantibodies to the pathogenic IgG2a and 2b subclasses by focusing on the role of the TLR-MyD88 pathways. Because the MyD88 pathway had been shown, in vitro, to provide a costimulatory signal for B cell stimulation by DNA (13,15) as well as potentially infl uence IgG class switching (21), we examined its in vivo role in the defi ned models of murine lupus we have established. To determine whether the MyD88 pathway contributed to the pathogenesis of a spontaneous lupus-like autoimmune disease, we generated the FcγRIIB −/− MyD88 −/− .B6 strain and compared autoantibody production and disease progression for this strain in comparison with the parental FcγRIIB −/− .B6 strain. MyD88 defi ciency resulted in the abrogation of IgG2a and 2b polyreactive anti-DNA and anti-GBM and anticardiolipin autoantibodies ( Fig. 1 A and Fig. 2). Susceptible mice lacking MyD88 did not demonstrate evidence of antibody deposition or tissue injury ( Fig. 1, B and C) and were protected from renal disease, as measured by accumulation of blood urea nitrogen (not depicted). In contrast with the parental FcγRIIB −/− .B6 strain, the FcγRIIB −/− MyD88 −/− .B6 strain was protected from the premature mortality associated with FcγRIIB −/− .B6 mice (2) and all animals survived beyond 9 mo of age ( Fig. 1 D).
Because MyD88 is common to many toll signaling pathways and is expressed in myeloid, lymphoid, and dendritic cell types (and to determine the contribution of specifi c TLRs and cell types to the protection seen in MyD88-defi cient FcγRIIB −/− .B6 mice), we turned to a spontaneous lupus model in which the development of autoimmunity is driven by intrinsic B cell defects, the anti-DNA knockin model 56R + FcγRIIB −/− .B6 (6,22,23). These mice already develop autoantibodies after 5 wk. The triple transgenic strain 56R + FcγRIIB −/− MyD88 −/− .B6 was thus compared with its heterozygous counterpart for the development of autoantibodies. As was the case with the FcγRIIB −/− .B6 model, defi ciency of MyD88 resulted in strong reduction of IgG autoantibodies in the serum of these mice (Fig. 3 A). In contrast, IgM anti-DNA titers derived from the 56R transgene (6) were only partially reduced in the MyD88-defi cient mice (Fig. 3, A). Among the autoreactive IgG subclasses and IgG1 was unaff ected by the absence of MyD88, whereas IgG2a and 2b were reduced to background levels ( Fig. 3 A).
The point at which the MyD88 pathway was required for development of anti-DNA antibodies of the IgG2a and 2b subclasses was investigated by FACS and single cell PCR analysis on B cells sorted for their state of maturation from MyD88-defi cient and -suffi cient backgrounds. We found no diff erences in B cell development or survival (Fig. 3  light chain usage in both MyD88-suffi cient and -defi cient animals ( Fig. 3 and Fig. S1). In contrast, IgG2a and 2b switched heavy chains with the anti-DNA 56R VDJ4 H transgene could not be detected in either germinal center (GC) (Fig. 3 F) or splenic plasma cells (Fig. 3 G) isolated from the MyD88-defi cient strain. Switching to the IgG2a and 2b subclasses was restricted to the endogenous alleles in the MyD88-defi cient strain. The selective abrogation of the anti-DNA response in the MyD88-defi cient 56R + FcγRIIB −/− . B6 strain was consistent with a failure of anti-self antibodies to switch to the IgG2a and 2b subclasses.

The loss of IgG2a and 2b autoantibodies in MyD88-defi cient mice is a B cell-intrinsic defect
To confi rm that the specifi c reduction in IgG2a and 2b autoantibody titers in MyD88-defi cient mice resulted from a defect of B cells to class switch to these specifi c subclasses, we examined the ability of 56R-expressing naive IgM + B cells to class switch to IgG subclasses in vitro (Fig. 4). Consistent with previous reports (21,24), we observed that stimulation of MyD88 +/− B cells with the TLR9 ligand CpG together with the B cell stimuli anti-CD40 and IL-4 resulted in the secretion of IgM and IgG antibodies (Fig. 4). In contrast, MyD88 −/− B cells were specifi cally defective in their ability to secrete IgG2a and 2b antibodies, whereas IgM secretion was unchanged and IgG1 secretion even increased (Fig. 4), thus indicating a cell intrinsic specifi c defect in the ability of MyD88-defi cient B cells to class switch to the IgG2a and 2b subclasses (25).

ARTICLE
TLR9 defi ciency abrogated class switching to pathogenic IgG2a and 2b anti-DNA/polyreactive autoantibodies The toll receptor mainly responsible for the abrogation of IgG2a and IgG2b anti-DNA antibodies was TLR9 because defi ciency in this receptor largely recapitulated the reduction of IgG2a and 2b anti-DNA autoantibodies observed for MyD88 defi ciency on the susceptible 56R + FcγRIIB −/− .B6 background as shown in Fig. 5. The TLR9 pathway was therefore required for the generation of specifi c anti-DNA IgG2a and 2b subclasses by providing a costimulatory signal for B cell stimulation by DNA (13). Recently, it has been suggested that TLR9 defi ciency abrogates anti-DNA antibodies, but not other autoantibodies, and does not protect from disease in another SLE mouse model (14). In contrast with those results, we observed that not only IgG2a and 2b anti-DNA autoantibodies but also anti-GBM and anticardiolipin autoantibodies of the IgG2a and 2b subclasses were reduced in 56R + FcγRIIB −/− TLR9 −/− .B6 mice as compared with 56R + FcγRIIB −/− TLR9 +/+ and +/− .B6 mice (Fig. 5). Preabsorbing the serum of 56R.FcγRIIB −/− .B6 mice with GBM and cardiolipin antigens reduced the amount of autoantibodies that recognized DNA suggested that at least a component of the autoantibodies was polyreactive in the 56R.FcγRIIB −/− B6 mice (Fig. 5 E) and that TLR9 deficiency reduced polyreactive IgG2a and 2b autoantibodies.
FACS and single cell PCR analysis of B cells showed that a high and equivalent percentage of heavy chains in naive B cells expressed the anti-DNA 56R VDJ4 H transgene in TLR9-defi cient animals ( Fig. 5 F [compare with Fig. 3] and not depicted). In contrast, IgG2a and 2b switched heavy chains with the 56R VDJ4 H transgene could not be detected in either splenic GCs or plasma cells isolated from the TLR9-defi cient strain (Fig. 5 F). Switching to the IgG2a and 2b subclasses was restricted to the endogenous or secondarily rearranged knockin allele in the TLR9defi cient strain.
No evidence of kidney pathology was observed in the 56R + FcγRIIB −/− TLR9 −/− .B6 mice and all mice survived beyond 8 mo of age in contrast with the premature mortality observed for 56R + FcγRIIB −/− TLR9 +/+ (unpublished data and reference 6). Thus, TLR9 defi ciency protected from pathology by inhibiting the generation of IgG2a and 2b polyreactive autoantibodies.

The loss of IgG2a and 2b autoantibodies in TLR9-defi cient mice is also a B cell-autonomous defect
To confi rm that the specifi c reduction in IgG2a and 2b autoantibody titers in TLR9-defi cient mice resulted from a defect of B cells, we examined the ability of 56R-expressing naive IgM B cells to class switch to IgG subclasses in vitro (Fig. 6 A). As was observed for MyD88 −/− B cells (Fig. 4), TLR9 −/− B cells were specifi cally defective in their ability to secrete IgG2a, 2b, and 3 antibodies in response to CpG, anti-CD40, and IL-4, whereas IgM secretion was unchanged and IgG1 secretion increased (Fig. 6 A), thus indicating a cell-autonomous specifi c defect in the ability of TLR9-defi cient B cells to class switch to the IgG2a, 2b, and 3 subclasses.
The selective defect in in vitro class switching of TLR9 and MyD88-defi cient B cells, with increased IgG1 and decreased IgG2a and 2b, has also been observed in B cells isolated from mice defi cient in the transcription factor T-bet (26). CpG has been shown in vitro to up-regulate T-bet expression in B cells in a TLR9-MyD88-dependent pathway (24). Our results suggested that one mechanism by which the TLR9-MyD88 pathway was specifi cally regulating the IgG2a and 2b anti-DNA/polyreactive autoantibody response could be through T-bet regulation. To determine if T-bet was induced in B cells isolated from the 56R + RIIB −/− TLR9 +/− or −/− strains, we examined the levels of T-bet transcripts in B cells derived from these two strains upon stimulation with CpG, anti-CD40, and IL-4. T-bet expression was ninefold higher in B cells derived from the 56R + RIIB −/− TLR9 +/− .B6 strain compared with B cells derived from the 56R + RIIB −/− TLR9 −/− .B6 strain (Fig. 6 B). Therefore, absence of TLR9 signaling resulted in less T-bet transcription (24,26). Given the ability of T-bet to induce class switching in a B cell autonomous mechanism (26), our results suggest that this pathway is a likely route for TLR9-MyD88 regulation of autoantibody class switching in vivo as well.

The loss of IgG2a and 2b autoantibodies in TLR9-defi cient mice was restricted to anti-self antibodies
The eff ect of TLR9 defi ciency on the reduction of IgG2a and 2b antibodies was restricted to autoantibodies because the number of plasma cells (CD138 + ) in spleen and bone marrow and the total serum level of all IgG subclasses were not reduced in 56R + FcγRIIB −/− TLR9 −/− .B6 mice compared with 56R + FcγRIIB −/− TLR9 +/+ and +/− .B6 mice (Fig. 7 A and not depicted). Furthermore, the specifi c IgG subclass response to NP-CGG (T-dependent) or NP-Ficoll (T-independent) immunization was not reduced in TLR9 −/− . B6 mice compared with TLR9 +/− .B6 mice (Fig. 7 B). Naive splenic B cells from the indicated genotypes were stimulated with 15 μg/ml CpG1826, 10 μg/ml anti-CD40, and 10 ng/ml rmIL-4 in vitro for 5 d and total Ig subclass concentrations in the supernatants were determined. Class switching to IgM was unchanged and to IgG1 increased in MyD88-defi cient backgrounds. In contrast, switching to IgG2a, 2b, and 3 was signifi cantly impaired.

D I S C U S S I O N
The TLR9-MyD88 pathway is required for the generation of pathogenic anti-DNA/polyreactive autoantibodies of the IgG2a and 2b subclasses in vivo, based on the analysis of the spontaneous SLE models described in this study. These subclasses effi ciently trigger infl ammatory responses by their ability to preferentially engage the activation receptor FcγRIV on macrophages (20). This skewing of autoantibody responses through the TLR9-MyD88 pathway promotes class switching to these pathogenic subclasses and provides an explanation for the predominance and pathogenicity of those antibodies in vivo. In the absence of TLR9, IgG2a and 2b autoantibodies were nearly as strongly reduced as in MyD88defi cient mice, suggesting that TLR9 is the main MyD88dependent inducer of IgG2a and 2b autoantibodies in our lupus-prone mice (Fig. 5). However, activation of other TLRs may be partly involved as described previously (15).
No changes in the accumulation of IgG1 autoantibodies were observed in mice defi cient in either MyD88 or TLR9. The fact that the number of IgG1-positive GCs or splenic plasma cells, which retained the intact 56R VDJ4 heavy chain, was not increased in 56R + RIIB −/− TLR9 −/− mice as compared with 56R + RIIB −/− mice, argues against an IgG1 default pathway in TLR9-defi cient mice that could com-pensate for the loss of IgG2a and 2b autoantibodies (unpublished data).
Recently, the role of TLR9 in SLE was investigated by generating F2 crosses of TLR9 −/− mice (on a mixed genetic background containing both B6 and 129Sv genomes) and Fas-defi cient MRL/Mp lpr/lpr mice (14). Consistent with our results, this TLR9 defi ciency abrogated anti-DNA antibodies; however, in contrast with our study, other autoantibodies persisted and the animals were not protected from disease. These diff erences most likely result from the diff erential contributions of genetic background to autoimmunity and disease progression in the mixed MRL/B6/129 background, thus accounting for the incomplete penetrance observed in those studies. We further suggest that the increased escape of polyreactive B cells from central tolerance we observed in FcγRIIB −/− .B6 mice (Figs. 3 and 5 and reference 6) more closely resembles the phenotype seen in pediatric SLE patients (16,17) than the Fas-defi cient phenotype, where a broadly based number of specifi c self-reactive B and T cells are activated and protected from death in the periphery. The activation of the immune system in Fas-defi cient mice probably depends to a greater extent on other MyD88 costimulators such as IL-1, IL-18, and other TLRs (27) than on TLR9.

ARTICLE
A likely mechanism by which TLR9 signaling can break tolerance and promote specifi c class switching to IgG2a and 2b is suggested by the in vitro induction of the transcription factor T-bet by CpG DNA through the TLR9-MyD88 pathway in B cells (Fig. 6 B and references 3, 24). Our results are thus consistent with the observation that T-bet defi ciency results in decreased IgG2a, 2b, and 3 levels in the lupus-susceptible strain MLR/lpr (26). However, in contrast with our results, IgG1 levels are increased in MRL/lpr mice defi cient in T-bet (26). This diff erence could refl ect the diff erences in the mouse models used in the two studies.
Our data thus suggest a model (Fig. S2, available at http://www.jem.org/cgi/content/full/jem.20052438/DC1) in which anti-DNA/polyreactive naive IgM + B cells that have escaped central tolerance can be induced to switch to the pathogenic IgG2a and 2b subclasses by stimulation of the TLR9-MyD88 pathway. This stimulation may occur through pathogen-derived or apoptotic DNA delivered to the endosomal TLR9 molecule by the anti-DNA B cell receptor (28), thus triggering TLR9/MyD88-dependent induction of T-bet expression and subsequent switching to IgG2a and 2b. These pathogenic subclasses are normally prevented from accumulation by the action of the inhibitory receptor FcγRIIB, which limits the expansion of plasma cells and secretion of autoreactive IgGs (6). The reduction of FcγRIIB in other autoimmune-susceptible strains (7,(29)(30)(31)(32) removes this checkpoint and allows for the expansion of plasma cells secreting these pathogenic subclasses. Deposition of immune complexes results in tissue pathology and premature mortality that occurs through engagement of FcγRIV expressed on myeloid eff ector cells (20). The identifi cation of the TLR9-MyD88 pathway as a critical pathway in determining the development of pathogenic polyreactive autoantibody subclasses in vivo provides the rationale for its targeting in disease like SLE.
Detection of antibodies specifi c for double-stranded DNA was done as described previously (6). In brief, ELISA plates were precoated with 5 μg/ml of methylated BSA (Sigma-Aldrich) followed by incubation overnight at 4°C with 50 μg/ml of calf thymus DNA (Sigma-Aldrich). After washing, the plates were blocked (PBS, 3% BSA, 1 mM EDTA, 0.1% gelatin) and subsequently incubated with 1/100 diluted serum. Bound antibodies were detected as described for the immunoglobulin isotype and subclass determination. IgG2a autoantibodies of 56R + B cells (haplotype: a ) were detected with an antibody against IgG2a a (Bethyl Laboratories) and IgG2a antibodies of B cells without 56R + (haplotype: b ) were detected with an antibody against IgG2a b (Bethyl Laboratories). Antibodies against nuclear proteins and DNA were detected with an ANA ELISA kit (Corgenix) and antibodies against GBM and cardiolipin were detected with kits from Hycor, according to the manufacturer's directions. Serum was diluted 1/100. Antibodies against NP were detected with NP(24)-BSA coated ELISA plates. Serum was diluted 1/300. Kidney pathology. Kidneys were fi xed with 10% formalin in PBS and embedded in paraffi n. Paraffi n-embedded sections were stained with hematoxylin and eosin. To assay for immune complex deposition and macrophage accumulation, kidneys were embedded in Tissue-Tek OCT compound and snap frozen. Sections (5 μm) were air-dried, fi xed with cold acetone, and stained with FITC-conjugated anti-mouse IgG subclass antibodies (anti-IgG1 and IgG3, Sigma-Aldrich; IgG2 a b [recognizing the C57BL/6 IgG2a protein] and IgG2b, Bethyl Laboratories), biotin-conjugated anti-mouse FcγRIV (20), and Cy3-conjugated antibiotin (Sigma-Aldrich) or PE-conjugated anti-mouse Mac-I (Becton Dickinson).
Single cell sorting, cDNA synthesis, and PCR. The single cell PCR methodology has been described previously (6). In brief, immature IgM a + AA4.1 + CD19 int bone marrow cells (knockin allele: IgM a ), IgM a + CD19 + B220 + splenocytes, FAS + GL7 + GC splenocytes, and CD-138 high plasma splenocytes from indicated mice were sorted by a FACS-Vantage (Becton Dickinson) cell sorter into 96-well PCR plates. Cells were lysed and cDNA was prepared as described. Transcripts were amplifi ed by two rounds of PCR (outer and inner primers; Fig. S3) with the following conditions: denaturating for 5 min at 94°C, 50 cycles of 30 s at 94°C, 30 s at 60°C, 55 s (fi rst PCR) or 45 s (second PCR) at 72°C, followed by fi nal elongation for 10 min at 72°C.
In vitro stimulation. Naive B cells were enriched by the MACS B cell depletion kit (Miltenyi Biotec). The purity was verifi ed by FACS analyses and found to be >97% B cells. The cells were cultured for 5 d in RPMI 1610, 10% FCS, 150 μg/ml streptomycin, 150 U/ml penicillin, and 5 μM 2-mercaptoethanol with the indicated concentrations of rmIL-4 (PeproTech), anti-CD40 (Becton Dickinson), and CpG1823 (InvivoGen). Supernatants were used for ELISA analyses and RNA for RT-PCR was prepared with the RNeasy Mini kit (QIAGEN).
RT-PCR. cDNA was prepared with the superscript III polymerase kit (Invitrogen). RT-PCR was performed with the SYBR green PCR Master Mix and the Applied Biosystems machine with the primers in Fig. S3.
Online supplemental material. Fig. S1 shows B cell development of MyD88-suffi cient and -defi cient mice characterized by FACS analyses. Fig. S2 represents a model depicted the B cell checkpoints involved in the generation of anti-DNA/polyreactive autoantibodies and systemic autoimmune disease. Fig. S3 lists the primers used for the paper. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20052438/DC1.